Short answer
GeneDx Holdings Corp. (WGS) filed its fiscal 2025 10-K annual report with the SEC on Feb 23, 2026. It reported revenue of $428M (+40.0% year over year) and net income of −$21M.
- Top risk flagged: Regulatory risk: $42M settlement agreement with third-party payor for alleged overpayments to Legacy Sema4, $2M remaining payments as of Dec 31, 2025
FY2025 key financial metrics · XBRL
- Revenue
- $428M
- +40.0% YoY
- Net income
- −$21M
- +59.8% YoY
- Operating margin
- -3.1%
- +4.5 pp YoY
- Gross margin
- 69.7%
- +6.1 pp YoY
- EPS (diluted)
- −$0.73
- +62.4% YoY
- ROE
- -6.8%
- +14.5 pp YoY
- Operating cash flow
- $33M
- +216.8% YoY
Source: XBRL data from the GeneDx Holdings Corp. (WGS) FY2025 10-K on SEC EDGAR. USD.
GeneDx Holdings Corp. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Provider of clinical exome and genome sequencing diagnostics powered by proprietary GeneDx Infinity™ rare disease dataset
- New emphasis on rapid and ultraRapid genomes, medium/long-read sequencing, and multimodal genomic analysis expansion in 2025
- Strategic shift: Accelerating industry leadership through integration of AI-powered variant interpretation and launching global market expansion with Fabric Genomics acquisition
- Quantitative metric: GeneDx Infinity™ dataset grew 30% in 2025, surpassing prior 24 years combined, includes 2.5M tests and 50% non-European genetic diversity
- Noteworthy fact: Leveraged AI (Multiscore) and cloud-based platforms to improve interpretation speed and scalability while lowering sequencing costs
Management Discussion & Analysis
- Forward-looking statements noted, but no specific management guidance or risk details given
Risk Factors
- Regulatory risk: $42M settlement agreement with third-party payor for alleged overpayments to Legacy Sema4, $2M remaining payments as of Dec 31, 2025
- Macroeconomic risk: reliance on reimbursement approvals from commercial and Medicaid payors, with 18% average reimbursement rate increase in 2025 impacting revenue
- Operational risk: dependency on third-party suppliers for diagnostic test components and data storage, affecting cost and service delivery efficiency
- Competitive risk: integration risk from Fabric Genomics acquisition to expand AI-enabled genome interpretation amid rapid technology evolution and competitors
- Financial risk: $57.2M non-cancellable operating leases and $29.2M finance leases creating fixed cash obligations impacting liquidity management
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.